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Abstract 
Background: Cervical cancer is the most common cancer in black South African 
women. Cervical cancer screening was initiated in South Africa in 2001, but limited 
infrastructure in the public health service result in a long delay between initial 
screening and colposcopy and treatment for women with abnormal Pap smears. 
 
Objective: To determine the effect of the time interval between cervical cytology 
screening and histology at treatment on the grade of cervical disease in women at 
a colposcopy clinic, Chris Hani Baragwanath Hospital. 
 
Methods: Women with cytological abnormalities were referred to the colposcopy 
clinic according to National Guidelines for referral. Data extracted from the 
colposcopy clinic database were analyzed to determine whether early (up to 180 
days) or late (more than 180 days) referral and treatment had an impact on the 
grade of dysplasia of the cervical lesion from the time of initial diagnosis on 
cervical cytology to the definitive treatment at colposcopy. 
 
Results: In the early (7 to 180 days) referral group 213 (13.43%) women 
compared to 201 (14.63%) in the late (181 to 1702 days) referral group had up-
grading of cervical dysplasia (p=0.35). The number of women with down-grading 
of dysplasia or no change in grade of dysplasia was 1373 (86.57%) and 1173 
(85.37%) in the early and the late referral groups respectively (p=0.35). In the 
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univariate analysis, risk factors for up-grading of dysplasia were HIV (OR=1.63, 
p=0.00) and condom use (OR=1.30, p=0.02). There were 4 cases (0.68%) of 
invasion in the LSIL group and 50 cases (2.11%) in the HSIL group that were not 
detected by cervical cytology. Risk factors for invasive disease on histology were 
age (OR=1.09 per year, p=0.00), parity (OR=1.32 per pregnancy, p=0.00) and 
HSIL on cervical cytology compared to LSIL (OR=3.17, p=0.03). 
 
Conclusion:  There was no difference in up or down-grading of cervical dysplasia 
between patients that were referred to colposcopy clinic within 180 days compared 
to those that arrived after 180 days. With the present restrictive infra-structure, 
older women, HIV positive women, those of higher parity, and especially those 
with HSIL on cervical cytology should be referred sooner. HIV positive women 
should be prioritised by grade of dysplasia but not by CD4 until its effect on 
cervical dysplasia has been clarified. Ideally all women should be seen at a 
colposcopy clinic at least within 180 days and even sooner because of other 
factors such as anxiety, loss to follow up and cases of invasion being missed by 
cytology. 
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Chapter 1 
This chapter discusses the impact of cervical cancer on the population and 
how screening has changed this. The problem of an ideal referral time 
between cervical cytology screening and colposcopy is addressed. We look 
at the role of HPV, HIV immunosuppression and ART usage on progression 
and regression of cervical dysplasia. 
 
Introduction 
Cervical cancer is a major health concern in South Africa and other developing 
countries. Overall the crude incidence rate of cervical cancer in South Africa is 
believed to be 22.8/100 000 compared to 15.8/100 000 globally (1). The last 
National Cancer Registry of 1999 estimated the lifetime risk of cervical cancer in 
black South African females to be 1 in 25, making it the most common cancer in 
black women in South Africa (2). The prevalence of pre-malignant cervical 
abnormalities in the Johannesburg Metropolitan area was equally high at 13.7% 
for any abnormality (3). Cervical cancer meets most of the WHO criteria for 
screening according to the Wilson-Jungner criteria (4). Screening and treatment of 
cervical cancer precursors have been shown to reduce the mortality from cervical 
cancer by 34-80% in developed countries (5).  
 
Prevention of cancer of the cervix became a National health priority in SA, where 
screening for cancer precursors with the Papanicolaou smear began in 2001 (6). 
The South African program has been developed in accordance with the 
recommendation by the WHO for mid-income countries. The recommendation 
 2 
being that cervical cytology screening should be performed 3 times in a woman’s 
lifetime, starting at the age of 35 at an interval of between 5-10 years to achieve 
80% coverage of the female population (7). (The SA program starts at the age of 
30 with an interval of 10 years) (6). 
 
For cervical cancer prevention to succeed, all aspects of the service need to be 
functional: screening, diagnosis (colposcopy and biopsy), treatment, and follow-up. 
Screening within the Johannesburg Metropolitan area is approximately 7% per 
year and this will translate into 70% coverage within 10 years (8). However, 
colposcopy services are overwhelmed by the large number of referrals which 
results in a delay in diagnosis and treatment.  An audit of the clinic at Chris Hani 
Baragwanath Academic Hospital showed that the average time from cervical 
cytology screening to the colposcopy visit between April 2003 and December 2006 
was 113 days. A quarter of the patients arrived within 51 days, and, by 104 days, 
half of the patients had attended. Three quarters of the patients had arrived within 
142 days. The range was 14 – 706 (9). 
 
Problem Statement 
The ideal time for referral to a colposcopy clinic, and its effect on the 
eventual outcome of the disease is still unclear and results from studies 
evaluating the course of untreated cervical cytological abnormalities are 
conflicting: 
 
 3 
Fakokunde has shown that amongst 316 women with high-grade smears, those 
seen after 180 days were less likely to need excisional treatment (33.8% vs. 
55.8% ; OR=0.45; 95% CI, 0.25-0.78; P=0.0004) and less likely to have high-
grade disease (24.3% vs. 45.9%; OR=0.37; 95% CI, 0.21-0.68; P=0.001) than 
women seen before 180 days. He found no significant difference between the 
groups in proportion of women with invasive disease (10). It is not known whether 
the same is applicable to our population and to the HIV positive population in 
whom more rapid progression has been demonstrated. Nappi found the risk of 
recurrence or progression of low-grade SIL to be about 4-5 times higher in HIV 
positive than HIV negative women (11). 
 
The UK’s National Health Service Cervical Screening Programme referral 
guidelines for colposcopy state that women should be examined in a colposcopy 
clinic within two weeks if their tests are reported as suspected cancer or glandular 
neoplasia, within four weeks if their tests show high grade disease (moderate or 
severe dyskaryosis) and within eight weeks if their tests show low grade disease 
(mild dyskaryosis or borderline changes) (12). Kirby felt that mild or moderate 
dyskaryotic smears should not be an indication for immediate referral for 
colposcopy, since under a conservative management policy most women return to 
normal without treatment (13). 
 
For study purposes it would be unethical to randomize patients into a referral 
interval of more than 180 days, but due to the excessive patient load and limited 
resources of doctors and nurses there is a long and variable waiting time in the 
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South African public sector.  We do not know whether the time interval between 
the cervical cytology screening and treatment affects the ultimate progression of 
disease in women in this setting.  
 
The current waiting time for an appointment at the colposcopy clinic at Chris Hani 
Baragwanath Academic Hospital is about 8 months. However, when cervical 
cytology reported the presence of malignant cells or when invasive disease 
couldn’t be excluded the patient was given an appointment for colposcopic 
assessment as soon as possible. The ideal time within which a patient with a 
cervical abnormality on cytology should attend colposcopy is not known. The 
situation is complicated by the fact that not all lesions will progress, and in fact 
some will regress. This study will therefore investigate the impact of referral times 
on the final histology. We will investigate the proportion and characteristics of 
change in severity of cervical dysplasia over time. 
 
Natural History and pathogenesis 
This section gives a short summary of HPV and its involvement in the 
pathogenesis of cervical dysplasia. Previously quoted progression and 
regression rates are presented. The interaction between HIV and HPV and its 
effect on cervical dysplasia is discussed. 
 
The Human Papillomavirus, of the Papovaviridae family, has been proven to be 
the most important causative factor in the development of cervical epithelial 
dysplasia and cervical cancer (14,15).  HPV’s detected in the cervix can be divided 
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into low risk types (HPV 6 and 11), intermediate risk types (HPV 31, 33 and 35) 
and the high risk types (HPV 16 and 18).  One to 15 % of cervical cancers test 
negative for HPV (14,15), this may reflect false negative test results or indicate a 
different type of cervical cancer (16). HPV infects the developing immature 
metaplastic cells of the transformation zone of the cervix. This viral infection is 
more often than not transient, because most individuals develop an effective type-
specific immune response. Pre-malignant and malignant cells arise as a result of 
HPV DNA integration into the host cellular genome, and overexpression of the 
viral E6 and E7 oncogenes. Cells acquire a proliferative advantage by escaping 
growth control exerted by p53 and p105Rb which are inactivated by E6 and E7 
proteins respectively (14). 
 
The long latency period between primary infection and emergence of invasive 
cancer, together with the finding that not all cases progress to invasive cancer, 
suggest that additional factors such as sexual behaviour, hormonal effects of oral 
contraceptives and pregnancy, dietary deficiencies, immunosuppression, chronic 
inflammation, genetic predispositions, tobacco use and socio-economical level are 
also involved in the process of tumour development (14,15). 
 
A meta-analysis by Melnikow found 7.13% of ASCUS and 20.81% of low-grade 
SIL progress to high-grade SIL after 24 months (17). Ostor described a 10% risk of 
progression from CIN1 to CIN3 and a 1% risk of progression from CIN1 to invasive 
cancer (18). Melnikow showed 0.25% of ASCUS, 0.15% of low-grade SIL and 
1.44% of high-grade SIL progressed to invasive cancer after 24 months (17), 
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whilst McCredie found that 31 to 51 % of untreated CIN3 progressed to invasive 
cancer after 30 years (19). 
 
Conversely, Melnikow also described that 68.19% of women with ASCUS on 
cervical cytology, 47.39% with low-grade SIL and 35.03% with high-grade SIL 
regressed to normal after 24 months (17) Ostor found a higher (60%) regression 
rate for CIN1 (18). 
 
Precursor lesions of the cervix persist longer and progress more quickly in women 
with high-risk HPV infections than in women with low-risk HPV infections, or 
without HPV. Schlecht et al found the mean times for regression from ASCUS to 
normal, from LSIL to ASCUS or normal, and from HSIL/CIN2 to ASCUS or normal 
were longer for women infected with high-risk HPV types (16.8 months, 13.8 
months, and 17.1 months respectively) than for women with low-risk HPV types 
(7.7 months, 7.8 months, 8.9 months), or for women with no HPV infection (7.6 
months, 7.6 months and 7.0 months respectively). Testing cervical lesions for 
high-risk HPV’s may help identify those that are likely to progress rapidly (20). 
 
HIV and cervical dysplasia 
The interaction between HIV and HPV and its effect on cervical dysplasia is 
discussed below: 
 
The burden of HIV in Sub-Saharan Africa is high, with an estimated prevalence of 
HIV infection of 29.8% amongst Gauteng antenatal attendees during 2009 (21). 
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HIV infection has changed the severity of HPV infection and the natural history of 
cervical dysplasia: In a US study, 60–70% of HIV-positive women tested positive 
for HPV, making them 2.3 times more likely to be infected than HIV-negative 
women. They were also 1.9 times more likely to be infected with multiple HPV 
strains, and 1.6 times more likely to have a higher HPV viral load (22). 
 
Palefsky et al found the prevalence of high risk HPV in HIV positive women to be 
20-34%, making them about 5 times more likely to have high risk HPV infection 
present than is the case in HIV negative women (23). Women with HIV were also 
more likely to have persistent infections with HPV (24). A low CD4 count has been 
found to increase the abovementioned likelihood ratios (22,23,24).  Women 
infected with both HIV and high-risk HPV had a more than 40 fold higher risk of 
SIL than uninfected women (25). 
 
It seems probable that this association between HIV infection and HPV infection 
plays an important role in the significantly higher prevalence of cervical cellular 
abnormalities observed in HIV positive women (26,27). However, most of these 
cytological abnormalities are LSIL; in HIV positive women in the US most 
abnormalities were ASCUS and low-grade SIL, with high-grade lesions diagnosed 
in less than 10% (28). Massad et al found in a group of 1639 HIV positive women 
that the proportion of women with high-grade lesions did not increase over a 
period of up to 5 years (29).  
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Ellerbrock found that one in five HIV-positive women developed biopsy-confirmed 
SIL’s within 3 years compared to 1 in 20 HIV-negative women with no evidence of 
cervical disease (30). Nappi found the risk of recurrence or progression of low-
grade SIL to be about 4-5 times higher in HIV positive than HIV negative women 
(11). 
 
Immune deficiency in HIV is associated with faster progression and slower 
regression of SIL. Massad demonstrated an OR of 1.1 for progression over a 
maximum period of 5 years in HIV positive women with a CD4>200 cells/mm3 and 
a viral load < 4000 copies/ml. When the CD4 was less than 200 cells/mm3 and the 
viral load >4000 copies/ml the OR was 1.7 for progression (29).  Six showed that 
over a period of one year, LSIL progressed to HSIL in 38.1% of HIV positive 
women with a CD4 count less than 500 cells/mm3, but there was no progression if 
the CD4 was more than 500 cells/mm3 (31). Regression of SIL was reduced by 
22% for every log10 increase in HIV viral load according to Schuman (26).  
 
Anti retroviral treatment may impact on the natural history of cervical disease in 
HIV-positive women, but the results of studies are contradictory so far. Minkoff 
found that women on HAART were 40% more likely to demonstrate regression 
and less likely to demonstrate progression (OR=0.68) over 6 monthly intervals 
(32). Lillo found no significant difference in progression over 6 months between 74 
women receiving HAART, 62 treated with one or two reverse transcriptase 
inhibitors only and 27 women not on treatment after adjusting for CD4 cell count 
(33). 
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HIV positive patients may need more frequent screening and a lower threshold for 
treatment due to the different behaviour of cervical dysplasia in these patients. In 
developed countries it is recommended that HIV positive women have two 
cytological assessments within the first year of HIV diagnosis and annually 
thereafter, with referral for colposcopy for any smear showing an ASCUS or more 
severe lesion (34). Faro et al recommends that in HIV-positive women, more 
frequent screening is recommended if HPV infection is known, if there has been a 
previous abnormal smear, if CD4 < 200 cells/mm3, or following any surgical 
treatment for cervical lesions (28).  
 
Study objectives 
Primary objective  
• To determine whether there is down-grading, the same grade of disease or up-
grading of disease associated with the two different referral intervals of less 
than 180 days compared to more than 180 days. 
 
Secondary objectives 
• To determine what proportion of patients have up-grading of dysplasia, have 
the same grade of disease, or down-grading of dysplasia between the 
predicted grade on cervical cytology and the actual grade on histology. 
• To determine the effect of HIV and CD4 count on up or down-grading of 
dysplasia and on the risk for invasive disease. 
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• To determine other risk factors for up-grading of dysplasia and invasive 
disease. 
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Chapter 2 
2.1. Methodology 
Study Design 
A cross-sectional analysis of data collected at the colposcopy clinic at Chris Hani 
Baragwanath Hospital was done. The data was prospectively recorded into the 
colposcopy database. Information on the demographic details (Age, parity, and 
contraception), HIV status, CD4 count, ART use, date of cervical cytology 
screening with results, colposcopy findings and the date of treatment with final 
histology result were used. Cervical cytology was assessed by conventional 
Papanicolaou smear. 
 
Study population 
The Colposcopy clinic at Chris Hani Baragwanath Hospital is a referral centre for 
Soweto and the Southern parts of Gauteng Province.  Between 2003/04/03 and 
2010/06/30, 3942 patients were referred to and seen at the clinic. 
 
Women with a clinically normal cervix (on speculum examination) and cervical 
cytology showing HSIL or more were referred to the colposcopy clinic although 
HIV infected women with a cervix which appeared normal in the presence of any 
cytological abnormality were also referred for colposcopy. HIV negative women 
with a LSIL were only referred if the cytological abnormality persisted after 12 
months.  When the presence of malignant cells were reported or when invasive 
disease could not be excluded the patient was referred for immediate colposcopic 
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assessment. Women with a clinically abnormal cervix but normal cervical cytology 
or without any cervical cytology result were also referred. 
Most of the cervical cytology specimens and all histology specimens were 
processed by the NHLS.  
 
The colposcopy clinic practices a policy of “see-and-treat”, where all women with 
cervical cytology showing HSIL or more and a colposcopic diagnosis of CIN 2 and 
more, or an inadequate colposcopy are treated with immediate LLETZ. HIV 
infected women with cervical cytology showing LSIL or more and colposcopy of 
CIN1 or more are also treated immediately. The Finesse I® and Finesse II® 
machines are used with the appropriate size of either a C-LETZ® or UtahLoop® to 
perform the LLETZ. 
 
2.2. Data Management and Statistical Analysis 
Exclusion criteria (see Fig. 3.1) 
• Patients who were referred with normal cytology and an abnormal cervix 
• Patients who had had a hysterectomy and were referred with a vault smear 
• Patients who were referred with a biopsy result rather than a cervical cytology 
result 
• When the date of the cervical cytology screening was unknown 
• When the cervical cytology reported “malignant cells” or “cannot exclude 
invasion” 
• When the cervical cytology was normal or showed ASCUS, ASC-H or AGC 
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Data cleaning and coding 
Data was extracted from the database on 2010/11/10, all the variables were put 
into an excel spreadsheet and coded for analysis. Missing data and outliers were 
re-checked on the NHLS system and on the Chris Hani Baragwanath Hospital 
record database for accuracy. Duplicate records were deleted.  
 
Missing HIV and CD4 results were updated from the NHLS system as explained: If 
the HIV result was unknown, then it was presumed to be positive if the CD4 was 
known and less than 500(n=20). Patients with an unknown HIV status at the first 
visit were regarded to be positive at that time if they tested HIV positive within a 6 
month period after this visit. Women who reported having had a negative test 
within the 6 months prior to the colposcopy visit were regarded as negative in this 
database.  If only the year was known when the patient was initially found to be 
HIV positive , then the month of diagnosis was entered as June (n=51). Only CD4 
results within 6 months before or after the first visit were recorded into the 
database. 
 
New variables were made for cervical cytology result, histology, types of treatment 
and contraception - these were categorized and coded.  
 
Descriptive statistics 
• Description of age, parity, contraceptive use, HIV status, CD4 count  
• Description of all cervical cytology results 
• Description of all the histological diagnoses 
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Analytical statistics 
The patients were divided into 3 referral interval groups: early (≤180 days), 
intermediate (between 180 and 360 days) and late referrals (≥360 days). However 
only 263 (8.89%) patients were in the late referral group. We decided to add them 
to the intermediate group because the differences observed between the early and 
intermediate group did not change whether the data were analysed using 2 or 3 
groups.  The change in severity of dysplasia between the two groups was 
compared. 
 
For comparisons of continuous data the T-test was used, for proportions Chi-
square was employed. A Logistic regression was performed to find factors which 
are associated with up-grading of dysplasia and invasive disease on histology.  
 
2.3. Ethics 
All women at the colposcopy clinic were counselled and requested to sign an 
informed consent form that allowed their data to be used for audit, follow-up and 
research. Patients that declined to give consent received the same treatment as all 
other patients. 
 
Permission to use information from the database was obtained from Dr Y Adam 
and Prof CJ van Gelderen. Ethical approval for the creation of the database had 
been obtained previously:  Clearance certificate number M090676. 
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Ethics approval for secondary analysis of this data was sought from and granted 
by the Human Research Committee of the University of the Witwatersrand. 
Clearance certificate number M10530 (See Appendix A for copy of certificate). 
 
Permission for this study was obtained from the CEO of Chris Hani Baragwanath 
Hospital. 
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Chapter 3 
3.1. Results 
After exclusion of certain patients, the final information extracted from the 
remaining 2960 patients is presented in detail below. Details on age, parity, 
contraceptive use, HIV status and CD4 cell count are summarized in table 
and diagram form. The reader is shown the proportions of cervical cytology 
results, colposcopy findings and the final histology results and how they 
compare with each other. Variables in the two referral interval groups are 
compared and p-values for each were calculated.  
 
Finally, the result of logistic regression shows the risk factors for invasive 
disease and/or up-grading of dysplasia.  
 
3.1. 1. Study population 
From 2003/04/03 to 2010/06/30, 3942 women were referred to the Chris Hani 
Baragwanath Colposcopy clinic.  
 
Eighty one patients with normal cervical cytology were referred because the 
clinician thought that the cervix was abnormal. ASCUS, AGC and ASC-H were 
excluded because there is no direct histological comparison/equivalent: high grade 
lesions may be seen in 10% to 39% of cases classified as AGC; 10% to 20% of 
women with Atypical Squamous Cells on cervical cytology are estimated to have 
underlying CIN2 or CIN3; underlying invasion may be present in 1 in 1000 (35). 
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Invasion or adeno-carcinoma in-situ patients would require urgent assessment and 
therefore looking at an ideal referral time would not make sense. Pregnant patients 
would only have a biopsy if the cervical cytology or colposcopy suggested a 
malignancy, LLETZ was thus postponed. Figure 3.1 shows the number of patients 
that were excluded from the analysis for the respective reasons: 
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Figure 3.1 Patients excluded from analysis. 
N=3942 
-21 (no Pap smear) 
3921 
-81 (Normal) 
-90 (ASCUS) 
-355 (ASCH) 
-13 (AGC) 
-133 (Invasion) 
-1 (Indeterminate) 
-2 (Adeno-carcinoma in-situ) 
3246 
-1 (Vault smear) 
-89 (Unknown 
cytology date) 
-2 (Insufficient 
information) 
3154 
-24 (Pregnant) 
-68 (LLETZ postponed for other reasons) 
-41 (LLETZ not done/necessary) 
2960 
-61 (Missing histology) 
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3.1.2. Cervical cytology findings 
Figure 3.2 shows the proportion of abnormalities according to cervical cytology. Of 
note was the high percentage of cytology findings that suggested invasion, this is 
expected because the screening programme in SA only started in 2003 and SA is 
a country with a very high incidence of cervical cancer. A longer established 
screening service may have identified these women earlier, when they still had a 
pre-malignant lesion. A larger than expected number of patients with LSIL were 
observed; this was probably because all cases of LSIL in HIV positive patients 
were referred, whereas HIV negative women were only referred if they had 
persistent LSIL. 
 
 
 
 
 
 
 
 
 
 
           
 
 
Figure 3.2 Incidence of cervical cytology abnormalities referred. 
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3.1.3. Age and parity 
The mean age was 36.94 (SD= 8.34) with a median of 35.63 (IQR= 31.01- 41.76) 
and the range 18 to 81.The South African screening programme starts at the age 
of 30 (6), so the above values would be expected to be higher. This is possibly 
due to the referral of many HIV positive patients in whom cervical cytology 
screening was done at an earlier age. The mean parity was 2.11 (SD= 1.46) with a 
median of 2 (IQR= 1-3). 
 
3.1.4. Contraception 
The method of contraception used by a woman was also recorded to 
determine whether there was any association with up or down-grading of 
disease.  
  
The age range in our patients was 18 to 81, so it must be kept in mind that this 
was not an accurate representation of women in their reproductive years. Condom 
use referred to both male and female condoms, although it was not specified on 
the database. Dual contraception referred to the use of a condom and any other 
modern method. Figure 3.3 gives a break-down of the contraceptive methods used 
by the women: 
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n= 2752 Condoms (30.49%)
None (24.71%)
Depot Provera (11.30%)
Nur-Isterate (9.38%)
NSA (6.65%)
COC (8.85%)
Sterilized (4.91%)
Dual (4.58%)
POP (0.76%)
Desiring Pregnancy
(0.62%)
IUCD (0.58%)
Pregnant (0.18%)
     
Figure 3.3 Contraceptive methods. 
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3.1.5. Colposcopy 
Colposcopy is performed by specialist Gynaecologists or by supervised registrars 
in our service. Colposcopic diagnosis is performed using a method based on the 
Reid Colposcopic Index (36). This is a systematic, objective method of 
colposcopically grading the severity of premalignant cervical lesions. The index 
considers four attributes of premalignant cervical lesions. The first three signs are 
evaluated following application of 5% acetic acid to the cervix. The last sign is 
dependent on a preliminary score of the first three signs and is determined after 
Lugol's iodine application to the cervix. 
The first sign considers the nature of the lesion margin. Low-grade lesion margins 
(0 points) are described as irregular, flocculated, feathered, angular or 
"geographic," indistinct, with "satellite" lesions or phytic micropapilliferous 
(condyloma-like) in contour. Intermediate lesion margins (1 point) are smooth and 
fairly straight. High-grade margins (2 points) exhibit raised peeling edges, or are 
proximally located within a larger low-grade lesion and have an internal border or 
demarcation between the area of low-grade change and the squamo-columnar 
junction. 
The second sign considers the colour of aceto-whitening. Low-grade lesions (0 
points) appear semitransparent or shiny snow white. High-grade lesions (2 points) 
are of a dirty oyster-gray color and dense appearing. An intermediate lesion (1 
point) is off-white, between the two extremes in the color spectrum. 
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The third colposcopic sign assesses vascular changes. The low-grade category (0 
points) is characterized by fine-caliber capillaries (punctation or a mosaic pattern). 
These vessels are not dilated and are configured in loose arcades. The 
intermediate category (1 point) displays an absence of superficial vessels. The 
high-grade category (2 points) features coarsely dilated vessels ( coarse 
punctation or mosaic). 
The final colposcopic sign is evaluated after staining of the cervix with Lugol's 
iodine. The low-grade category (0 points) may take up iodine (mahogany-brown 
color) or reject iodine (mustard-yellow color). The intermediate category (1 point) 
displays a variegated yellow-brown or "tortoise-shell" appearance resulting from 
partial or inconsistent iodine uptake. The high-grade category (2 points) rejects 
iodine (mustard-yellow). Some low-grade lesions, all high-grade lesions, columnar 
cells, and atypical immature squamous metaplasia reject iodine (mustard-yellow). 
Therefore, a preliminary summated index score of the first three colposcopic signs 
influences the score for the last colposcopic sign. 
Scores between zero and 2 are predictive of mild dysplasia (CIN I) or human 
papillomavirus infection. Scores between 3 and 5 are suggestive of mild or 
moderate dysplasia (CIN I or CIN II).  Total scores of 6 to 8 are predictive of 
moderate or severe dysplasia. In our clinic iodine staining is not used as part of 
this staging and there is a degree of subjectivity. Figure 3.4 gives a breakdown of 
the different colposcopy findings.  
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Figure 3.4 Colposcopy findings.
 
3.1.6. HIV 
The accuracy of HIV negative status was limited by the fact that it was ascertained 
by self-report in many women, and could not be corroborated. The stigma 
surrounding HIV is still a big problem in SA and this further limits the accuracy of a 
reported negative test result. Women who reported a negative test within 6 months 
of the colposcopy visit were recorded as negative in the database. HIV status was 
recorded as unknown if the woman tested negative more than 6 months before. 
HIV testing had only been offered routinely to all women attending the clinic since 
2006, and some women declined to be tested.  
 
Of 2947 patients, 19.10% were HIV negative, 69.63% were HIV positive and in 
11.27% the HIV result was unknown. Of the HIV positive patients, the mean CD4 
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count was 267.19 (SD= 181.76) and the median CD4 was 230 (IQR= 131-366). 
ART’s were being used by 41.81% of the HIV positive patients.  
 
The high proportion of HIV positive women may in part be due to HIV positive 
women having cervical cytology screening at an earlier age and due to the strong 
association between HIV and SIL’s.  
 
3.1.7. Referral time 
The referral time was calculated from the date of cervical cytology screening until 
the day of the first Colposcopy clinic visit. The mean referral time was 199.29 days 
(SD= 140.64), median referral interval was 169 days (IQR= 112.50- 263) with a 
range of 7 to 1702. 
 
The 2960 patients were divided into two arbitrary groups according to referral 
interval: those seen up to 180 days (group 1) and those seen after 180 days 
(group 2). The SA guidelines from 2003 do not give a specific timeframe within 
which a patient must be seen (6); women are given the first available appointment. 
Using these time scales, 1586 (53.58%) patients arrived within 180 days and 1374 
(46.42%) patients were seen after 180 days. 
 
3.1.8. Histology findings compared to Cervical cytology result  
Amongst 2808 patients, treatment options included LLETZ in 2666 (94.94%), 
hysterectomy in 67 (2.39%) and cone biopsy in 40 (1.42%). In 35 (1.25%) patients, 
only a punch biopsy was done. The aim of treatment 
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lesion, since positive margins have been shown to be a predictor of persistence 
(2). Amongst 2693 patients, 273 (10.14%) had both margins involved by dysplasia, 
1143 (42.44%) had complete excision margins, 897 (33.31%) had involvement of 
the ectocervical margin, 253 (9.39%) had endocervical margin involvement and in 
127 (4.72%) margin involvement was not known. 
 
Four cases of invasion in the LSIL group and 50 cases in the HSIL group had not 
been detected on cervical cytology. 
 
Figure 3.5 gives a breakdown of the histological abnormalities found in those 
patients where cervical cytology showed LSIL compared to those with HSIL: 
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Figure 3.5 Comparison of histology findings in LSIL and HSIL group. 
 
3.1.9. Comparison of referral groups 
The variables in the two referral-interval groups were compared (Table 3.2); HIV 
status, CD4 count, grade of dysplasia and invasion on cervical cytology showed 
significant differences, but histology findings did not. 
 
It is interesting to see that there were more women with a CD4 count less than 200 
cells/mm3 in group 1, perhaps this was because they were more ill and sought 
medical care sooner or because the appointment system was biased towards 
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giving these women an earlier appointment. More HIV positive women in group 2 
were on ART, this is probably because they have had more time to be initiated. 
 
There were also more women with HSIL in group 1 (1292, 54.56%) than in group 2 
(1076, 45.44%), again this could be because of the same bias mentioned above. 
 
There were 33 (58.25%) women with invasive disease in group 1 compared to 20 
(41.75%) in group 2. Although not statistically significant, this could be because 
invasive disease is more likely to be symptomatic; also, women with a clinically 
suspicious cervix are referred immediately. 
 
The ideal would be to compare histology with histology because then the actual 
progression or regression of disease can be determined. Because we are 
comparing cytology to histology we can merely suggest progression or regression 
of dysplasia because it is well known that there are discrepancies between 
cervical cytology and histology. The sensitivity and specificity of the Papsmear is 
78.2% and 85.6% respectively for CIN2 and worse as diagnosed on histology (37). 
This would obviously affect the accuracy of all our findings. For the purpose of this 
study, we use the terms “up-grading of dysplasia” when cervical cytology showed 
LSIL and the histology showed at least CIN2 or more, or when cervical cytology 
showed HSIL and invasion on histology. “Down-grading of dysplasia” was defined 
as a HSIL or LSIL on cervical cytology with normal histology or a HSIL with CIN1 
or less on histology.  
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Table 3.1 Comparison of demographic and other variables in the two referral 
interval groups 
 
Referral interval  
< 180 days 
Referral interval 
 >180 days 
 
N (%) = 2960 (100%) 1586 (53.58%) 1374 (46.42%)  
Age 
Mean= 36.71 (SD=8.39) 
Median=35.14 (30.84-41.60) 
Range= 18.25-81.68 
Mean= 37.20 (SD= 8.27) 
Median= 36.16 (31.25-41.90) 
Range= 18.62-81.70 
P= 0.11* 
P= 0.07** 
HIV Positive N= 1009 (34.09%) N=1043 (35.24%) 
HIV Negative N= 342 (11.55%) N= 221 (7.47%) 
HIV Unknown N= 235 (7.94%) N= 110 (3.72%) 
P= 0.00 (Chi2) 
Known CD4 
N= 919 
Mean= 253.19 (SD= 179.70) 
Median= 210 (114-355) 
Range= 2-980 
N= 964 
Mean= 280.55 (SD= 182.79) 
Median= 244.50 (145-377.50) 
Range= 1-1222 
P= 0.00* 
P= 0.00** 
CD4<200 N= 837 (44.08%) N=446 (48.16%) N= 391 (40.18%) 
CD4= 200-350  
N= 533 (28.07%) 
N= 239 (25.86%) N= 294 (30.22%) 
CD4>350 N= 529 (27.86%) N=241 (26.03%) N= 529 (27.86%) 
HIV positive using ART N=365 (36.17%) N=493 (47.27%) 
P= 0.00(Chi2) 
Cytology LSIL N= 294 (49.66%) N= 298 (50.34%) 
Cytology HSIL N= 1292 (54.56%) N= 1076 (45.44%) 
P= 0.03 (Chi2) 
Histology CIN1 N=161 (50.79%) N= 156 (49.21%) P= 0.29 (Chi2) 
Histology CIN2 N= 478 (56.57%) N= 367 (43.43%) P= 0.04 (Chi2) 
Histology CIN3 N= 833 (53.09%) N= 736 (46.91%) P= 0.57 (Chi2) 
Micro-invasion N= 8 (47.06%) N= 9 (52.94%) P= 0.59 (Chi2) 
Invasion N= 25 (67.57%) N= 12 (32.43%) P= 0.09 (Chi2) 
Up-graded N= 213 (13.43%) N= 201 (14.63%) 
Down-graded/ 
same 
N= 1373 (86.57%) N= 1173 (85.37%) 
P= 0.35 (Chi2) 
*T-test, ** Mann-Whitney 
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Table 3.2 shows some demographic and other variables and their effect on the 
likelihood for histology to show invasive disease which was not suspected on 
cervical cytology. It also shows the effect of these variables on the rate of up or 
down-grading from cervical cytology (LSIL or HSIL) to histology. Logistic 
regression was used to calculate the odds ratio, significant differences were 
highlighted and only these will be discussed. 
 
Table 3.2 Effect of demographic details and other variables on invasive disease 
and up-grading of dysplasia 
 
Invasive disease (Univariate) Any up-grading 
 
Age 
 
1.09 OR p=0.00 (1.07-1.13) 
 
1.01 OR  p=0.39 (0.99-1.02) 
 
Age (Older than 30 compared to 
younger than 30) 
13.59 OR p= 0.01 (1.89-98.44) 1.07 OR  p=0.62 (0.82-1.39) 
 
Cytology HSIL as compared to LSIL 3.17 OR p=0.03 (1.14-8.81) 
 
Not done 
Referral every 3 months 
 
1.00  OR p=0.97 (0.85-1.19) 
 
1.03 OR  p=0.35 (0.97-1.10) 
 
Parity 
 
1.32 OR p=0.00 (1.13-1.53) 
 
0.96 OR  p=0.31 (0.90-1.04) 
 
HIV positive compared to HIV negative 0.37 OR p=0.00 (0.20-0.68) 
 
1.63 OR  p=0.00 (1.21-2.20) 
 
For every 100 cells increase in CD4, 
 if HIV infected 
1.15 OR p= 0.15 (0.95-1.40) 
 
1.05 OR  p=0.16 (0.98-1.12) 
 
The use or ART in women who are 
HIV infected 
0.54  OR p=0.17 (0.22-1.29)  0.99 OR  p=0.91 (0.78-1.26) 
 
Nur-Isterate® 0.51 OR p=0.26 (0.16-1.64) 0.76 OR  p=0.14 (0.52-1.10) 
 
Depo-Provera® 0.27 OR p=0.07 (0.06-1.10) 0.73 OR  p=0.07 (0.51-1.03) 
 
Combined Oral Contraceptives 0.22 OR p=0.23 (0.04-2.13) 
 
1.02 OR  p= 0.09 (0.66-1.58) 
 
Condoms 0.54 OR p=0.06 (0.28-1.03) 1.30 OR  p=0.02 (1.05-1.62) 
 Sterilization 1.47 OR p=0.47 (0.52-4.12) 0.86 OR  p=0.55 (0.53-1.41) 
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Chapter 4 
The extent of the burden of HIV infection and cervical cancer is reflected in 
our results. This chapter will begin with a discussion of these results, the 
limitations and strengths of the study and will end with recommendations 
regarding referral times and further studies.  
 
4.1. Discussion 
HIV status 
The HIV infection prevalence among patients was 69.63 % which is much higher 
than the estimated 30.30% among antenatal attendees in Gauteng during 2007 
(21). This is in keeping with the strong association between HIV and cervical 
dysplasia. Moodley found women infected with both HIV and high-risk HPV had a 
more than 40 fold higher risk of SIL than women infected with neither of these 
viruses (24). Schuman found the incidence rate for SIL’s among HIV-positive 
women was 11.5 cases/100 person-years of observation, compared with 2.6 
cases/100 person-years of observation among HIV-negative women (RR, 4.5; 
95% confidence interval CI, 3.1–6.4; P<.001) (26). 
 
However, this figure may also be high because HIV positive women were referred 
with a report of any cytological abnormality; HIV negative women were only 
referred if they had persistent equivocal results. 
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The mean CD4 count of 267 is quite low; this is also in keeping with the known 
association of a low CD4 count and cervical dysplasia. Firnhaber showed that the 
prevalence ratio for LSIL and HSIL were 2.5 if the CD4 was <200 compared to a 
prevalence ratio of 1 if the CD4 was >500 (38). Agaba found the median CD4 cell 
count was lower in women with dysplasia compared to those without (142 vs. 170 
cells/mm3; P=0.04) (39). In this study we were not able to control for ART use, 
duration of ART use and CD4 count. Of the HIV positive women, 41.81% were 
already on ART’s. This is a high proportion, considering that national ART ‘roll-out’ 
only began in 2001 at a very slow pace. 
 
Referral interval 
The mean referral interval was 199.29 days, which is equal to approximately 28 
weeks. Only 53.58% of patients had a referral interval of less than 180 days 
compared to 76.6% in the study done by Fakokunde (10). This interval is much 
longer than the intervals recommended in the UK (12). The longest referral time of 
1702 days (approximately four and a half years) is shocking. Regrettably, the 
retrospective nature of the study resulted in individual reasons for such long 
referral intervals remaining speculative.  
 
We do not know the actual proportion of patients that are lost to follow-up, but a 
longer referral interval would surely worsen this problem. We try to decrease loss 
to follow-up by using a “see-and-treat” policy and by not delaying colposcopy with 
repeat cervical cytology if a patient is seen after a very long referral interval. 
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Although there is a long waiting list due to poor infrastructure, poor education and 
poor socioeconomic conditions may also contribute to such long intervals. The 
lack of a policy in SA that addresses the referral interval is also an important 
contributing factor. 
 
Histology 
We found no significant difference in up or down-grading of dysplasia between the 
two referral-interval groups. This is in contrast to the findings of Fakokunde who 
showed that amongst 316 women with high-grade smears, those seen after 180 
days were less likely to need excisional treatment (33.8% [25/74] vs. 55.8% 
[135/242]; OR=0.45; 95% CI, 0.25-0.78; P=0.0004) and less likely to have high-
grade disease (24.3% [18/74] vs. 45.9% [111/242]); OR=0.37; 95% CI, 0.21-0.68; 
P=0.001) than women seen before 180 days. He found no significant difference 
between the groups in proportion of women with invasive disease (10). 
 
It must be kept in mind that the study by Fakokunde (10) was done in a developed 
country with the resources to use histology, the gold standard, to determine 
whether excisional treatment was necessary or not. Our colposcopy clinic 
however, uses a “see-and-treat” policy because it saves costs and time and also 
decreases the number of patients that would be lost to follow-up. The 
disadvantage of this policy is that more women receive excisional treatment which 
is associated with short term morbidities such as bleeding, pain and infection. 
Long-term morbidity includes cervical stenosis and there may also be an 
association with pre-term labour. 
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It is possible that the referral-intervals between the two groups were too short to 
show any significant results because of the slow progression of cervical dysplasia. 
Two studies demonstrated this effect: McCredie showed that 31 to 51 % of 
untreated CIN3 progressed to invasive cancer after 30 years (19). Melnikow 
showed that 20.81% of low-grade SIL progressed to high-grade SIL after 24 
months; 0.15% of LSIL and 1.44% of HSIL progressed to invasive cancer after 24 
months (17).   
 
Risk factors 
One would expect risk factors for invasion to be the same as those for up-grading 
of cervical dysplasia, but this was not true for age, parity, HIV status or use of 
condoms. This could be because of the slow progression of cervical dysplasia to 
cancer and because some of these dysplastic lesions may regress over time. 
 
Age 
The national cancer registry showed that the risk of developing cancer of the 
cervix increased with age, peaking at 136.4 per 100 000 in women between the 
ages of 65 and 69 in 1999 (2). Lomalisa (40) et al and Moodley (41) et al however 
showed that HIV positive patients presented with invasive cervical cancer 10 to 15 
years earlier than patients that were HIV negative. Fakokunde found that among 
those women who received treatment, age over 35 years was associated with an 
increased risk (6.1% [4/66] vs. 2.1% [3/74]; p=0.4) of invasive disease (10). This is 
confirmed in our study where for every year increase in age, a woman was 9% 
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more likely to have cancer on histology. Age was however not a risk factor for up-
grading of dysplasia, but the reason for this is unclear 
 
Parity 
For each child a woman had, the risk for invasion on histology was 32% higher. 
Parity had no effect on the risk of up-grading of cervical dysplasia. 
HIV 
HIV positive women had a smaller risk for invasion but an increased risk for up-
grading of dysplasia compared to HIV negative women, with odds ratios of 0.37 
and 1.63 respectively. Progression of LSIL was about 4-5 times higher in HIV 
positive than HIV negative women according to Nappi et al (11). This contradiction 
is difficult to explain. The decreased likelihood of invasive disease in HIV positive 
women may be due to these women dying from opportunistic infections before 
dysplasia can progress to cancer (40) or because they have more regular cervical 
cytology screening and are referred for colposcopy sooner. The total number of 
cases of invasion were however too small to determine the actual relationship. The 
increasing uptake of ART’s in SA may change this association in time. 
 
CD4 
The CD4 count was not a risk factor for invasive disease or for up-grading of 
dysplasia. This is in contrast to other studies. Massad showed an OR of 1.1 for 
progression in HIV positive women with a CD4>200 cells/mm3 and a viral load < 
4000 copies/ml. Women with a CD4 <200 cells/mm3 and a viral load >4000 
copies/ml had an OR of 1.7 for progression over a maximum period of 5 years 
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(29). Six showed that over a period of one year, LSIL progressed to HSIL in 38.1% 
of HIV positive women with a CD4 count less than 500 cells/mm3, but there was no 
progression if CD4 was >500 cells/mm3 (31). Our finding is very difficult to explain; 
one would have to do a longitudinal cohort study looking at HPV infection, grade of 
dysplasia, viral load, serial CD4 and ART usage to confirm this finding and explain 
it.  
  
Hormonal Contraception 
Nur-Isterate® and Depo-Provera® had no significant effect on up or down-grading 
of cervical dysplasia nor the risk for invasive disease on histology. Multiple studies 
have been done to assess the effect of injectable progestogen contraceptives on 
cervical neoplasia, there seems to be some association but not very strong (42). 
 
Our study found no association between COC and up-grading of dysplasia or 
invasive disease. Multiple studies have found an association between COC’s and 
cervical SIL and malignancy, but this is possibly due to a difference in sexual 
behaviour.  Women who do not use COCs usually use barrier methods of 
contraception, so they have an extra protection against HPV. COC users usually 
start having sexual intercourse at an earlier age, have more sexual partners, and 
rarely use barrier methods of contraception as compared to women using other 
contraceptives (43). 
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Condoms 
Condom use was protective for invasion (although not statistically significant) and 
also a risk factor for up-grading of dysplasia. This is difficult to explain, but perhaps 
this is due to reverse causality, where HIV positive women are more likely to use 
condoms when they know their status. 
 
ART usage 
The use of ART’s had no effect on the risk for invasive disease or the up-grading 
of dysplasia in our study. Studies have been contradictory so far: Minkoff found 
that women on HAART were 40% more likely to demonstrate regression and less 
likely to demonstrate progression (OR=0.68) at 6 monthly intervals (32). Lillo found 
no significant difference in progression between 74 women receiving HAART, 62 
treated with one or two reverse transcriptase inhibitors only and 27 women not on 
treatment after adjusting for final CD4 count at 6-monthly intervals (33). Lillo et al 
found cervical disease progression to be independent of HIV treatment (33). 
 
4.2. Strengths 
Our study has improved a lot on the study by Fakokunde et al; our study 
population was much bigger (2960 women vs. 316 women). Fakokunde only 
studied patients with HSIL, whereas we studied patients with both HSIL and LSIL 
(10). We also investigated the effect of other variables such as parity and 
contraception on cervical dysplasia. Fakokunde briefly mentions that there was no 
difference in immune status between the two referral interval groups, but it seems 
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that he did not investigate the effect of HIV on the need for excisional treatment or 
the likelihood of invasive disease (10). 
 
4.3. Limitations 
• Cytology (a screening test) was compared with histology (gold standard). 
Therefore actual progression or regression of cervical dysplasia can not be 
proven, but merely suggested. 
• HIV negative status was ascertained by self-report. HIV infection is a 
stigmatized condition so women may say they are negative when they are 
positive. Our results may thus be biased in the under-reporting of HIV 
infection. HIV testing has only been offered to all women attending the clinic 
since 2006, and some women declined testing. 
• Most CD4 counts were known, but viral loads were not. 
• We do not have information on all risk factors for progression of dysplasia 
such as smoking, sexual history and HPV-subtype. Duration and 
consistency of contraceptive use was not explored. 
• HIV negative women with LSIL were only seen at the colposcopy clinic if 
there was persistent equivocal cytology. 
• ART regimen and period of treatment were not known. 
• The indication for cervical cytology screening was not known and not all 
were necessarily for routine screening. 
• The retrospective nature of this study 
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4.4. Conclusion 
Our study has shown that a delay between cervical cytology screening and 
colposcopy of less than 180 days compared to more than 180 days had no effect 
on up or down-grading of cervical dysplasia. It is also extremely important to note 
that invasive disease not detected on cervical cytology was present in 2.79% of 
patients. 
 
HIV was shown to be a risk factor for up-grading of dysplasia. Contrary to other 
studies and our own expectation, CD4 count had no effect on up or down-grading 
of cervical cytology. Also unexpectedly, the use of condoms was found to be a risk 
factor for up-grading of dysplasia. 
 
In addition, risk factors for invasive disease were identified, these are: age, parity 
and HSIL on cervical cytology.  
 
Finally, the exact factor that determines whether dysplasia will regress or become 
invasive remains elusive. We found the risk factors for up-grading of dysplasia 
differed from those for invasion. Perhaps long-term studies involving large cohorts 
of women may explain this contradiction. 
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4.5. Recommendations for cervical cancer screening and 
colposcopy referral policies 
Although there was no significant difference in up-grading of dysplasia between 
the two referral-interval groups, women should all be seen at a colposcopy clinic at 
least within 180 days and even sooner because of other factors such as anxiety, 
loss to follow up and the finding of invasion being missed by cervical cytology.  
 
With the present restrictive infra-structure, older women, HIV positive women, 
those of higher parity, and especially those with HSIL on cervical cytology should 
be referred sooner. HIV positive women should be prioritised by grade of dysplasia 
but not by CD4 until its effect on up or down-grading of dysplasia has been 
clarified 
 
The South African cervical cancer screening program does not differentiate 
between HIV positive and HIV negative women, although HIV infected women are 
offered cervical cytology screening at the time of their diagnosis (as part of their 
package of care). Management of minor cytological abnormalities in HIV infected 
women is different mainly because of the uncertainty regarding their prognosis.  
HIV positive women are more likely to have cervical dysplasia and up-grading of 
dysplasia. The finding in this study that HIV positive women are less likely to have 
invasive disease needs to be corroborated in longitudinal cohorts. Certainly in SA, 
with more women on ART’s this association may change. 
 
 
 41 
4.6. Suggested improvements for future studies 
Only long term cohort studies in both HIV infected and uninfected women will 
inform better management in all aspects of the “Cervical Cancer Prevention 
program”. 
 
Cervical pre-malignancy and malignancy in HIV infected women require special 
study because of the known association between HPV and HIV.  Accuracy of HIV 
status, serial CD4 counts, Viral loads, HPV sub-typing and ART use will aid in 
assessing the risk of invasive disease in women who are HIV infected. 
Investigating the number of patients lost to follow up and the associated factors 
will aid in deciding which measures should be put in place to attempt to minimise 
this problem. 
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